Low dose continuous combined hormone replacement therapy: early and late postmenopausal effect on endometrium.

We investigated endometrial response to low (25 microg through the skin estradiol plus 700 microg norethindrone) and standard dose (2 mg oral estradiol plus 1 mg norethindrone acetate or 700 microg norethindrone) continuous combined therapy in postmenopausal women with time and bone mineral density response. Endometrial thickness was distributed logarithmically, with the means after use of 25 microg estradiol (4.3 mm) and 2 mg estradiol (3.8 mm) being similar. Subjects studied 15.4 +/‐ 7.0 months apart showed a difference of endometrial thickness of ‐0.55 +/‐ 1.3 mm. Neither pretreatment bone mineral density nor change correlated with endometrial thickness. Age, estrogen dose, bone mineral density, weight, and time on treatment do not relate to endometrial thickness. A commonly regarded cutoff point for biopsy, an endometrial thickness of 8 mm, is about 1 SD greater than the mean.

[1]  A. Fleischer,et al.  Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. , 1999, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[2]  M. Boulvain,et al.  Measurement of endometrial thickness with transvaginal ultrasonography: is it reproducible? , 1998, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[3]  H. Genant,et al.  Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .

[4]  H. Genant,et al.  Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.

[5]  Atkins Cd.  Postmenopausal hormone therapy and mortality. , 1997 .

[6]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[7]  T. R. Holbert.  Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy. , 1997, American journal of obstetrics and gynecology.

[8]  M. Wells,et al.  Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. , 1997, European journal of obstetrics, gynecology, and reproductive biology.

[9]  W. Holzgreve,et al.  Uterine perfusion and endometrial thickness in postmenopausal. women on long‐term continuous combined estrogen and progestogen replacement , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[10]  S. Cummings,et al.  Bone Mineral Density and Risk of Breast Cancer in Older Women: The Study of Osteoporotic Fractures , 1996 .

[11]  S. Cummings,et al.  Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. , 1996, JAMA.

[12]  M. Dören,et al.  Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. , 1996, Maturitas.

[13]  J. Risteli,et al.  Effects of low‐ and conventional‐dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women , 1996, European journal of clinical investigation.

[14]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[15]  M. Davie,et al.  Added effect of progestogens on bone mineral density response to oestrogen , 1996, Clinical endocrinology.

[16]  S. Evans,et al.  Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post‐menopausal ages , 1996, Clinical endocrinology.

[17]  D. Levine,et al.  Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. , 1995, Radiology.

[18]  M. Dören,et al.  Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. , 1995, American journal of obstetrics and gynecology.

[19]  F. Bonilla-musoles,et al.  Transvaginal color Doppler assessment of endometrial status in normal postmenopausal women: the effect of hormone replacement therapy. , 1995, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[20]  T. Naessén,et al.  Effect of chronic daily oral administration of 17βoestradiol and norethisterone on the isoforms of serum gonadotrophins in post‐menopausal women , 1995, Clinical endocrinology.

[21]  E. Gratacós,et al.  Transvaginal sonography of the endometrium in postmenopausal women: monitoring the effect of hormone replacement therapy. , 1994, Maturitas.

[22]  S. Soong,et al.  Transvaginal Sonography of the Endometrium in Postmenopausal Women , 1991, Obstetrics and gynecology.

[23]  D. Pretorius,et al.  Endometrial thickness after menopause: effect of hormone replacement. , 1991, Radiology.

[24]  A. Schauer,et al.  Vaginosonography for early detection of endometrial carcinoma? , 1990, The Lancet.

[25]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[26]  Ian W. B. Grant.  Introductory Medical Statistics , 1976, Journal of the Royal College of Physicians of London.

[27]  J. Reginster,et al.  The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis , 1998 .

[28]  J. Kanis,et al.  Perspective : The diagnosis of osteoporosis , 1994 .